Jiabao Renhe, a Leading Integrated Service Provider in Reproductive Genetics, Secures Series B+ Financing from Xingze Capital with Hoyo Capital as Exclusive Financial Advisor

Peking Jabrehoo Med Tech Co., Ltd., a Chinese integrated service provider in reproductive genetics, recently announced the completion of its Series B+ financing round, raising nearly RMB 100 million. The funds will be primarily used for the research and development of innovative products in the field of reproductive genetics and the comprehensive promotion of its integrated service platform. Apricot Capital served as the sole investor in this round, while HoYue Capital continued to act as the exclusive financial advisor.

In recent years, driven by factors such as the rising prevalence of infertility, delayed childbearing age, and improved household economic status, the assisted reproductive technology (ART) industry has entered a golden period of development. Statistics show that the annual number of in vitro fertilization (IVF) cycles in China has now exceeded 900,000. Moreover, the needs of infertile patients have evolved from simply achieving pregnancy to pursuing eugenics for healthier offspring. The advancement and widespread application of innovative technologies—including pre-conception screening, infertility screening, and preimplantation genetic testing and diagnosis—have provided clinicians and patients with more options.

In the field of reproductive and genetic innovation, Jabrehoo has become the largest integrated service platform in China. Since its establishment in 2011, the company has been dedicated to the clinical translation and innovative R&D of products related to assisted reproduction, genetics, and eugenics. It provides a one-stop, closed-loop solution for reproductive genetics to couples undergoing assisted reproduction, patients with infertility, and individuals preparing for pregnancy. These solutions include testing products based on high-throughput sequencing technologies, as well as non-sequencing products comprising related equipment, consumables, and management software. Furthermore, Jabrehoo is actively promoting the localization of various testing services.

As the first company in China to introduce NGS technology into PGT testing, Jabrehoo has cumulatively tested over 180,000 embryo samples. Among these, more than 43,000 samples underwent PGT-M testing, a clinical necessity, covering over 510 types of monogenic diseases and involving 6,100 families. The company possesses China’s largest S-PGD database for monogenic diseases, helping numerous families welcome healthy newborns. Meanwhile, the company’s PGT-A kit previously received the “Special Approval for Innovative Medical Devices” from the NMPA, and its wholly-owned subsidiary, Jabao Medical Laboratory, obtained the first CAP accreditation in the field of assisted reproduction in 2019.

“Striving for Perfection in Every Life” has always been the mission of Peking Jabrehoo Med Tech Co., Ltd. to make innovative reproductive genetics technologies accessible to more families in need.According to relevant data, institutions outside China’s first-tier cities that have obtained approval for preimplantation genetic diagnosis (PGD) account for only 12.8% of all assisted reproductive technology (ART) centers, and the overall number of preimplantation genetic testing (PGT) cycles represents less than 4% of total ART cycles. This indicates substantial room for growth compared to the approximately 30% penetration rate observed in the United States. Leveraging its first-mover advantage in technological leadership and a deep understanding of clinical needs, Jabrehoo’s PGT product series now covers more than 80% of reproductive medicine centers with PGD qualifications across mainland China. The company actively collaborates with clinical clients to promote the translation of scientific research into practical applications. By serving partners through multiple dimensions—including comprehensive product sales, continuously enhanced technical systems, localized technical support, and tiered service offerings—Jabrehoo has achieved zero churn among its core customers.

Currently, Peking Jabrehoo Med Tech Co., Ltd. has achieved full layout across the entire closed-loop industrial chain for reproductive genetics. Furthermore, it has established close collaborative relationships with strategic partners. In terms of future product system development, Peking Jabrehoo will further shift its focus from “enabling conception” to “optimizing birth outcomes,” thereby covering a broader market of couples preparing for pregnancy. Statistics show that the number of couples preparing for pregnancy in China currently reaches approximately 68 million per year, among whom the rate of neonatal birth defects is as high as 5.6%. Additionally, according to the requirements set forth in the National Comprehensive Prevention and Control Plan for Birth Defects released by the National Health Commission in 2018, “the rate of pre-conception eugenic health examinations shall reach 80% by 2022.” This indicates substantial market potential for pre-conception screening in the future.

Peking Jabrehoo Med Tech Co., Ltd. is well-positioned to seize greater opportunities by leveraging its capabilities in multi-scenario, cross-disciplinary clinical translation and product innovation. Reproductive genetics constitutes the core strategic focus of Peking Jabrehoo. Evolving from a leading enterprise in preimplantation genetic testing (PGT) to a pioneer in providing closed-loop solutions for eugenics and healthy reproduction, the company will align with national policies and collaborate with partners to remain customer-centric. While continuing to refine its flagship PGT testing products, Peking Jabrehoo will significantly upgrade other related offerings and develop diverse genetic screening and testing products across multiple platforms to meet varying needs, thereby helping patients transition from merely achieving pregnancy to ensuring optimal reproductive outcomes.

Fei Jia, Founder of JabrehooPeking Jabrehoo Med Tech Co., Ltd. stated that over the years, it has witnessed the rapid development of China’s assisted reproductive technology (ART) market and gained a profound understanding of the industry’s demand for superior technologies and services. Adhering to the principle that “one must be strong oneself to forge iron,” the company has remained committed to pragmatic operations and continuous internal improvement. By collaborating closely with clinical practitioners to facilitate the translation of numerous scientific achievements into practical applications, Jabrehoo has consistently provided high-quality solutions to families seeking fertility assistance, setting multiple industry-leading records. As a pioneer in reproduction and genetics, the company is obligated and well-equipped to continuously deliver advanced technologies, products, and services to society, growing alongside its clients and helping Chinese families realize their aspirations for eugenics and healthy offspring. The “Ai Wuxian Health Public Welfare Fund,” jointly established by Jabrehoo and the China Primary Health Care Foundation, has commenced operations. Reflecting Jabrehoo’s social responsibility, the fund has begun accepting project applications related to continuing medical education for physicians, translation of scientific research outcomes, and assistance for impoverished families, thereby contributing to the overall enhancement of diagnostic and therapeutic standards within the industry. We extend our sincere gratitude to Apricot Capital for its investment in this round, as well as to our supportive clients, partners, Haoyue Capital, shareholders, relevant organizations, and every dedicated employee.

Liu Wenyi, Founding Partner of Apricot CapitalIt stated that assisted reproductive technology (ART) and next-generation sequencing (NGS) are sectors with strong long-term prospects. Peking Jabrehoo Med Tech Co., Ltd. is the first company in China to introduce NGS technology into ART, leveraging advanced technologies to tap into the growing market of essential needs, which aligns closely with our investment philosophy. After years of dedicated efforts, Jabrehoo has emerged as a leading enterprise in the field of ART testing, spearheading technological and conceptual innovations. Apricot Capital hopes to grow alongside Jabrehoo, supporting the company’s clinical translation and innovative development in ART, genetics, and eugenics, thereby providing more comprehensive solutions for couples undergoing ART and individuals preparing for pregnancy. We firmly believe that, under the leadership of Mr. Fei and his team, the company will undoubtedly elevate this niche industry to new heights, ultimately benefiting patients and the general public.

Liu Hao, Founder and CEO of Haoyue Capitalstated that there is still a significant unmet demand for reproductive services in China’s assisted reproductive technology (ART) market, indicating substantial future market potential. Fei Jiahe, founder of Peking Jabrehoo Med Tech Co., Ltd., and its management team have long been committed to translating scientific achievements and driving technological innovation in the field of reproductive genetics, providing comprehensive integrated solutions for patients with infertility. The company has consistently ranked among the industry leaders in multiple dimensions, including market share, scale of embryo databases, and diagnostic capabilities for rare diseases. With the rapid development of the reproductive health industry, we are optimistic that Jabrehoo will continue to deepen its presence in the ART market, benefiting more families with fertility needs in the future.